Weight-Loss Surgery Outperforms Ozempic in New Study Findings

Weight-Loss Surgery Outperforms Ozempic in New Study Findings

A groundbreaking study reveals that weight-loss surgery proves to be five times more effective than the popular weekly injections of GLP-1 receptor agonists, such as semaglutide, commercially known as Ozempic, and tirzepatide, branded as Mounjaro.

This significant finding emerged during the American Society for Metabolic and Bariatric Surgery’s Annual Scientific Meeting held in Washington. The research involved an analysis of real-world electronic medical records from a staggering 51,085 patients at NYU Langone Health and NYC Health + Hospitals.

Research Overview

The participants all had a body mass index (BMI) of at least 35. They either underwent bariatric surgeries, specifically sleeve gastrectomy or Roux en-Y gastric bypass, or were prescribed injectable medications like semaglutide or tirzepatide between the years 2018 and 2024.

Sleeve gastrectomy, a common procedure, reduces the stomach’s size, assisting obese patients in weight loss. In contrast, gastric bypass modifies the digestive tract by bypassing a section of the small intestine, as detailed by the Mayo Clinic.

Weight Loss Results

Two years post-surgery, patients who underwent bariatric procedures experienced an average weight loss of 58 pounds. In stark contrast, patients who received a GLP-1 prescription and adhered to the treatment for at least six months reported a meager weight loss of 12 pounds, according to the researchers.

These findings translate into substantial differences in total weight loss percentages, with surgical patients exhibiting 24% total weight loss versus only 4.7% for those using injectable medications.

It is worth noting that patients on GLP-1 drugs for a full year did achieve more significant weight loss, approximately 7%, though this still falls short of surgical efficacy.

The Divergence from Clinical Trials

Interestingly, these results stand in contrast to clinical trial data that typically report weight loss of between 15% and 21% for GLP-1 medications. Dr. Avery Brown, the study’s lead author and a surgical resident at NYU Langone Health, pointed out that real-world results appear to be considerably lower, even for patients with active prescriptions for an entire year.

High Discontinuation Rates

According to Dr. Brown, a substantial 70% of patients prescribed GLP-1 medications will discontinue their use within a year. This raises crucial implications for those considering these treatments.

“GLP-1 patients may need to adjust their expectations and adhere more closely to the treatment. Alternatively, they might consider metabolic and bariatric surgery to achieve desired results,” Dr. Brown advised.

Future Research Directions

In light of these findings, the research team intends to investigate additional strategies to enhance outcomes for patients who rely on GLP-1 medications. Moreover, they plan to identify which patients are better suited for either surgical procedures or injectable alternatives.

Prevalence of GLP-1 Versus Surgery

The use of GLP-1 drugs has surged in popularity, with studies indicating that approximately 12% of Americans have used these medications at some point. However, current statistics suggest that only 6% of individuals are actively using them at present.

Despite this accessibility, it is disheartening that more than half of patients abandon GLP-1 medication after a year. Alarmingly, about 72% stop after two years, according to various studies. This punctuates the challenges associated with long-term medication adherence.

Low Surgery Rates

Despite meeting surgical eligibility criteria, only about 1% of eligible patients underwent bariatric procedures in 2023, as reported by the ASMBS. This disparity highlights the ongoing challenges in addressing obesity treatment options.

Funding and Sponsorship

The study received funding from the National Center for Advancing Translational Sciences at the National Institutes of Health. Meanwhile, Novo Nordisk, the manufacturer of Ozempic and Wegovy, declined to comment on the study’s findings when approached.

Industry Approaches

In addition to reaching out to Novo Nordisk, Fox News Digital contacted researchers involved in the study and Eli Lilly, the company behind Mounjaro and Zepbound, but responses remain pending.

A Shift in Treatment Perspectives

The implications of this study are profound. As more patients and healthcare professionals seek effective solutions for weight management, this research underscores the critical need to weigh the benefits of surgery against those of pharmaceutical interventions. With obesity rates on the rise, understanding the long-term effectiveness of these options could reshape treatment paradigms for patients nationwide.

The conversation regarding optimal weight loss strategies will continue to evolve as additional research and clinical insights emerge, paving the way for informed decisions that can ultimately improve patient outcomes in the realm of weight management.